Topical antimicrobial agents for pediatric burns

Lindberg RB, Moncrief JA, Switzer WE, Order SE, Mills W Jr. The successful control of burn wound sepsis. J Trauma. 1965;5:601–16. Pruitt BA Jr, O’Neill JA Jr, Moncrief JA, Lindbergh RB. Successful control of burn wound sepsis. JAMA. 1968;203:1054–6. Brown TP, Cancio LC, McManus AT, Mason AD. Survival benefit conferred by topical antimicrobial preparations in burn patients: a historical perspective. J Trauma. 2004;56:863–6. Warriner R, Burrell R. Infection and the chronic wound: a focus on silver. Adv Skin Wound Care. 2005;18(8):2–12. Dai T, Huang YY, Sharma SK, Hashmi JT, Kurup DB, Hamblin MR. Topical antimicrobials for burn wound infections. Recent Pat Antiinfect Drug Discov. 2010;5:124–51. Glasser JS, Guymon CH, Mende K, Wolf SE, Hospenthal DR, Murray CK. Activity of topical agents against multi-drug resistant bacteria recovered from burn patients. Burns. 2010;36:1172–84. Pensler JR, Herndon DN, Ptak H, Bonds E, Rutan TC, Desai MH, et al. Fungal sepsis: an increasing problem in major thermal injuries. J Burn Care Rehabil. 1986;7:488. Greenhalgh DG, Saffle JR, Holmes JH, Gamelli RG, Palmieri TL, Horton JW, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28:776–90. Kass EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Phys. 1956;69:56–63. Kass EH. Chemotherapeutic and antibiotic drugs in the management of infections of the urinary tract. Am J Med. 1955;18:764–81. Robson MC. Wound infection: a failure of wound healing caused by an imbalance of bacteria. Surg Clin North Am. 1997;77:637–50. Barsoumian A, Sanchez CJ, Mende K, Tully CC, Beckius ML, Akers KS, et al. In vitro toxicity and activity of Dakin’s solution, mafenide acetate, and amphotericin B on filamentous fungi and human cells. J Orthop Trauma. 2013;27(8):428–36. Lineweaver W, McMorris S, Soucy D, Howard R. Cellular and bacterial toxicities of topical antimicrobials. Plast Reconstr Surg. 1985;75:394–6. Wasiak J, Cleland H, Campbell F, Spinks A. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev. 2013;(3) https://doi.org/10.1002/14651858.CD002106.pub4. Barajas-Nava LA, López-Alcalde J, Roqué i Figuls M, Solà I, Bonfill Cosp X. Antibiotic prophylaxis for preventing burn wound infection. Cochrane Database Syst Rev. 2013;(6) https://doi.org/10.1002/14651858.CD008738.pub2. Deitch EA, Wheelahan TM, Rose MP, Clothier J, Cotter J. Hypertrophic burn scars: analysis of variables. J Trauma. 1983;23:895–8. Neely AN, Gardner J, Durkee P, Warden GD, Greenhalgh DG, Gallagher JJ, et al. Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? J Burn Care Res. 2009;30:19–29. Marx DE, Barillo DJ. Silver in medicine: the basic science. Burns. 2014;40 S:S9–S18. Fong J, Woods F. Nanocrystalline silver dressings in wound management: a review. Int J Nanomedicine. 2006;1(4):441–9. Lansdown A. Silver 1: its antibacterial properties and mechanism of action. J Wound Care. 2002;11:125–13. Dunn K, Edwards-Jones V. The role of ActicoatTM with nanocrystalline silver in the management of burns. Burns. 2004;30(Supp 1):S1–9. Poon VKM, Burd A. In vitro cytotoxity of silver: implication for clinical wound care. Burns. 2004;30:140–7. McCauley RL, Linares HA, Pelligrini V, Herndon DN, Robson MC, Heggers JP. In vitro toxicity of topical antimicrobial agents to human fibroblasts. J Surg Res. 1989;46(3):267. Fraser JF, Cuttle L, Kempf M, Kimble RM. Cytotoxicity of topical antimicrobial agents used in burn wounds in Australasia. ANZ J Surg. 2004;74:139–42. Cho Lee AR. Effect of silver sulfadiazine on skin cell proliferation and wound healing process in the hairless mouse 2nd degree burn model. J Pharm Investig. 2002;32:113–7. Moyer CA. Treatment of large human burns with 0.5% silver nitrate solution. Arch Surg. 1965;90:812–67. Fox CL. Silver sulfadiazine: a new topical therapy for Pseudomonas infection in burns. Arch Surg. 1968;96:184–8. Carr HS, Wlodkowski TJ, Rosenkranz HS. Silver sulfadiazine: in vitro antibacterial activity. Anrimicrob Agents Chemother. 1973;4:585. Heyneman A, Hoeksema H, Vandekerckhove D, Pirayesh A, Monstrey S. The role of silver sulphadiazine in the conservative treatment of partial thickness burn wounds: a systematic review. Burns. 2016;42:1377–86. Fuller FW. The side effects of silver sulfadiazine. J Burn Care Res. 2009;30:464–70. Hoffmann S. Silver sulfadiazine: an antibacterial agent for topical use in burns. Scand J Plast Reconstr Surg. 1984;18:119–26. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: review of the literature. Burns. 2007;33:139–48. Aziz Z, Abu SF, Chong NJ. A systematic review of silver-containing dressings and topical silver agents (used with dressings) for burn wounds. Burns. 2012;38:307–18. Wright J, Lam K, Burrell RE. Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. Am J Infect Control. 1998;26:572–7. Wright J, Lam K, Hansen D, Burrell RE. Efficacy of topical silver treatment against fungal burn wound pathogens. Am J Infect Control. 1999;27:344–50. Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial action of Acticoat antimicrobial barrier dressing. J Burn Care Rehabil. 1999;20:195–200. Tredget EE, Shankowsky HA, Groeneveld A, Burrell R. A matched pair randomized study evaluating the efficacy and safety of Acticoat silver coated dressings for treatment of burn wounds. J Burn Care Rehabil. 1998;19:531–7. Paddock HN, Fabia R, Giles S, Hayes J, Lowell W, Besner GE. A silver impregnated antimicrobial dressing reduces hospital length of stay for pediatric patients with burns. J Burn Care Res. 2007;28:409–11. Brown M, Dalziel SR, Herd E, Johnson K, Wong She R, Shepherd M. A randomized controlled study of silver-based burns dressing in a pediatric emergency department. J Burn Care Res. 2016;37:e340–7. Malic C, Verchere C, Arneja SN. Inpatient silver sulphadiazine versus outpatient nanocrystalline silver models of care for pediatric scald burns: a value analysis. Plast Surg. 2014;22(2):99–102. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. Cochrane Database Syst Rev. 2010;(3):CD006478. https://doi.org/10.1002/14651858.CD006478.pub2. Demling R, DeSanti L. The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns. 2002;28:264–6. Chen J, Han CM, Lin XW, Tang ZJ, Su SJ. Effect of silver nanoparticle dressings on second degree burn wounds. Zhonghua Wai Ke Za Zhi. 2006;44:50–2. [article in Chinese, abstract in English] Innes M, Umraw N, Fish J, Gomez M, Cartotto R. The use of silver-coated dressings on donor site wounds: a prospective controlled matched pair study. Burns. 2001;27:621–7. Perdue GF, Hunt JL. Chondritis of the burned ear. Am J Surg. 1986;152(3):257–9. Kucan JO, Smoot EC. Five percent mafenide acetate solution in the treatment of thermal injuries. J Burn Care Rehabil. 1993;14:158–63. Ibrahim A, Fagan S, Kearney T, Sarhane KA, Hursey DA, Chang P, et al. A simple cost-saving measure: 2.5% mafenide acetate solution. J Burn Care Res. 2014;35(4):349–53. Palmieri TL, Greenhalgh DG. Topical treatment of pediatric patients with burns: a practical guide. Am J Clin Dermatol. 2002;3(8):529–34. Monafo WW, West MA. Current treatment recommendations for topical burn therapy. Drugs. 1990;40:364–73. Armstrong DG, Bohn GB, Glat P, Kavros SJ, Kirsner R, Snyder R, et al. Expert recommendations for the use of hypochlorous solution: science and clinical application. Ostomy Wound Manage. 2015;61(5 suppl):4S–18S. Heggers JP, Sazy A, Stenberg BD, Strock L, McCauley RL, Herndon DN, Robson MC. Bactericidal and wound healing properties of sodium hypochlorite solutions: the 1991 Lindberg Award. J Burn Care Rehabil. 1991;12:420–4. Coetzee E, Whitelaw A, Kahn D, Rode H. The use of topical unbuffered sodium hypochlorite in the management of burn wound infections. Burns. 2012;38:529–33. Halstead FD, Rauf M, Moiemen NS, Bamford A, Wearn CM, Fraise AP, et al. The antibacterial activity of acetic acid against biofilm producing pathogens of relevance to burns patients. PLoS One. 2015; https://doi.org/10.1371/journal pone.0136190. Cooper ML, Boyce ST, Hansbrough JF, Foreman TJ, Frank DH. Cytotoxicity of cultured human keratinocytes (HK) to topical antimicrobial agents. J Surg Res. 1990;48:190–5. Greenhalgh DG. Topical antimicrobial agents for burn wounds. Clin Plast Surg. 2009;36:597–606. Miller LM, Loder JS, Hansbotough JF, Peterson HD, Monafo WW, Jordan MH. Patient tolerance of topical chlorhexidine diphosphanilate: a new topical agent for burns. Burns. 1990;16(3):217–20. Stern HS. Silver sulphadiazine and the healing of partial thickness burns: a prospective clinical trial. Br J Plastic Surg. 1989;42:581–5. Garner JP, Heppell PSJ. Cerium nitrate in the management of burns. Burns. 2005;31:539–47. Scholten-Jaegers SMHJ, Niewenhuis MK, van Baar ME, Niemeijer AS, Hiddingh J, Beerthuizen GIJM. Epidemiology and outcome of patients with burns treated with cerium nitrate silversulfadiazine. J Burn Care Res. 2017;38:e432–42. Fox CL Jr, Monafo WW Jr, Ayvazian VH, Skinner AM, Modak S, Stanford J, et al. Topical chemotherapy for burns using cerium salts and silver sulfadiazine. Surg Gynecol Obstet. 1977;144:668–72. Munster AM, Helvig EI, Rowland S. Cerium nitrate–silver sulpha–diazine cream in the treatment of burns: a prospective evaluation. Surgery. 1980;88(5):658–60. Koller J, Orsag M. Our experience with the use of cerium sulphadiazine in the treatment of extensive burns. Acta Chir Plast. 1998;40(3):73–5.